Agenus (AGEN) announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab in patients with microsatellite stable metastatic colorectal cancer will be presented at the 2025 European Society for Medical Oncology Gastrointestinal Cancers Congress in Barcelona, Spain. A poster presentation will feature updated findings from an expanded cohort of 123 patients, incorporating additional participants and extended follow-up to further assess clinical activity of the combination, including durability of response and overall survival, the company noted.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGEN:
- Biotech Alert: Searches spiking for these stocks today
- Agenus price target raised to $4 from $3 at Baird
- Agenus’s Regulatory and Clinical Developments Prompt Neutral Stance Amid Uncertain FDA Pathway
- Agenus Inc. Reports Q1 2025 Progress and Financials
- Agenus Inc. Earnings Call: Optimism Amid Challenges